Free Trial

Rein Therapeutics (RNTX) Earnings Date, Estimates & Call Transcripts

Rein Therapeutics logo
$1.19 +0.02 (+1.71%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Rein Therapeutics Earnings Summary

Rein Therapeutics released Q3 2025 earnings on November 14, 2025, reporting an EPS of -$0.21, which beat analysts' consensus estimates of -$0.24 by $0.03. With a trailing EPS of -$1.96, Rein Therapeutics' earnings are expected to grow next year, from ($1.63) to ($1.33) per share.

Q3 2025 Earnings Resources

Consensus EPS
(Nov. 14)
-$0.24
Actual EPS
(Nov. 14)
-$0.21 Beat By $0.03
Get Rein Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rein Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

RNTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Rein Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.49-$0.49-$0.49
Q2 20261-$0.49-$0.49-$0.49
Q3 20261-$0.35-$0.35-$0.35
Q4 20261-$0.35-$0.35-$0.35

Rein Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/14/2025Q3 2025-$0.24-$0.21+$0.03-$0.21--
8/14/2025Q2 2025-$0.22-$0.28 -$0.06-$0.28--
5/15/2025Q1 2025-$0.21-$0.25 -$0.04-$0.25--
4/7/2025Q4 2024--$0.26--$1.89--

Data powered by Fiscal.ai.

Rein Therapeutics Earnings - Frequently Asked Questions

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earning data on Friday, November 14, 2025. Learn more on RNTX's earnings history.

In the previous quarter, Rein Therapeutics (NASDAQ:RNTX) reported ($0.21) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.24) by $0.03. Learn more on analysts' earnings estimate vs. RNTX's actual earnings.

Rein Therapeutics (NASDAQ:RNTX) has a recorded net income of -$49.87 million. RNTX has generated -$1.96 earnings per share over the last four quarters.

Rein Therapeutics' earnings are expected to grow from ($1.63) per share to ($1.33) per share in the next year.


This page (NASDAQ:RNTX) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners